Be part of InnoMedica – Participate in the capital increase 2019 from 1st April until 31st May. The public offering of 103,516 shares at CHF 226.60 per share asks for a minimum subscription of 60 shares.
Vistit us at our capital increase events.
* mandatory item
Patented technology – based on many years of research
Improved efficacy despite dose reduction due to multi-level glycan targeting – basic therapeutic cytostatic agents for the first time applied specifically in tumor tissu
Operating license from Swissmedic for proprietary clean room facility for GMP-production obtained
Together for the patient – planning of clinical trials in collaboration with Swiss Group for Clinical Cancer Research (SAKK)
Chemotherapy is considerably more tolerable by the use of targeting systems reducing side-effects to a minimum
Drug delivery is poised to change the way doctors practice medicine – The Scientist, 2014
Reduced side effects – healthy tissue is optimally protected by the liposomal encapsulation of the drug
Existing agent subject to innovation – simpler registration with Swissmedic due to already approved active agent
©Copyright Innomedica 2016